The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Preclinical efficacy and clinical safety of clinical‐grade nebulized allogenic adipose mesenchymal stromal cells‐derived extracellular vesicles
Open accessAbstract
Mesenchymal stromal cell‐derived extracellular vesicles (MSC‐EVs) turn out to be a promising source of cell‐free therapy. Here, we investigated the biodistribution and effect of nebulized human adipose‐derived MSC‐EVs (haMSC‐EVs) in the preclinical lung injury model and explored the safety of nebulized haMSC‐EVs in healthy volunteers. DiR‐labelled haMSC‐EVs were used to explore the distribution of nebulized haMSC‐EVs in the murine model. Pseudomonas aeruginosa‐induced murine lung injury model was established, and survival rate, as well as WBC counts, histology, IL‐6, TNF‐α and IL‐10 levels in bronchoalveolar lavage fluid (BALF) were measured to explore the optimal therapeutic dose of haMSC‐EVs through the nebulized route. Twenty‐four healthy volunteers were involved and received the haMSC‐EVs once, ranging from 2 × 10 8 particles to 16 × 10 8 particles (MEXVT study, NCT04313647). Nebulizing haMSC‐EVs improved survival rate to 80% at 96 h in P. aeruginosa‐induced murine lung injury model by decreasing lung inflammation and histological severity. All volunteers tolerated the haMSC‐EVs nebulization well, and no serious adverse events were observed from starting nebulization to the 7th day after nebulization. These findings suggest that nebulized haMSC‐EVs could be a promising therapeutic strategy, offering preliminary evidence to promote the future clinical applications of nebulized haMSC‐EVs in lung injury diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acute respiratory distress syndrome
Thompson, B. T., Chambers, R. C., & Liu, K. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1608077 · Cited by 1,807
Ratajczak, J., Wysoczynski, M., Hayek, F., Janowska-Wieczorek, A., & Ratajczak, M. Z. (2006) · Leukemia · doi:10.1038/sj.leu.2404296 · Cited by 1,340
MSC-NTF (NurOwn®) exosomes: a novel therapeutic modality in the mouse LPS-induced ARDS model
Kaspi, H., Semo, J., Abramov, N., Dekel, C., Lindborg, S., Kern, R., Lebovits, C., & Aricha, R. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02143-w · Cited by 68
Shi, M., Zhu, Y., Yan, J., Rouby, J., Summah, H., Monsel, A., & Qu, J. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.287 · Cited by 30
Self-citation
Cited by
Mesenchymal stromal/stem cell (MSC)-Derived exosomes in clinical trials
Lotfy, A., AboQuella, N. M., & Wang, H. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03287-7 · Cited by 482
Jia, Y., Yu, L., Ma, T., Xu, W., Qian, H., Sun, Y., & Shi, H. (2022) · Theranostics · doi:10.7150/thno.74305 · Cited by 391
Xu, G., Jin, J., Fu, Z., Wang, G., Lei, X., Xu, J., & Wang, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02312-w · Cited by 269
Self-citationStem cell-based therapy for pulmonary fibrosis
Cheng, W., Zeng, Y., & Wang, D. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03181-8 · Cited by 65
Mitigation of influenza-mediated inflammation by immunomodulatory matrix-bound nanovesicles
Crum, R. J., Huckestien, B. R., Dwyer, G., Mathews, L., Nascari, D. G., Hussey, G. S., Turnquist, H. R., Alcorn, J. F., & Badylak, S. F. (2023) · Science Advances · doi:10.1126/sciadv.adf9016 · Cited by 25
Metadata
- Authors
- Shi, M., Yang, Q., Monsel, A., Yan, J., Dai, C., Zhao, J., Shi, G., Zhou, M., Zhu, X., Li, S., Li, P., Wang, J., Li, M., Lei, J., Xu, D., Zhu, Y., & Qu, J.
- Venue
- Journal of Extracellular Vesicles
- Publisher
- Wiley
- Published
- 2021-08
- Volume
- 10
- Issue
- 10
- Pages
- e12134-e12134
- ISSN
- 2001-3078 (ISSN-L)
- OpenAlex
- W3195750155
- Cited by
- 224
- References
- 4
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical efficacy and clinical safety of clinical‐grade nebulized allogenic adipose mesenchymal stromal cells‐derived extracellular vesicles. https://app.cochat.ai/papers/10.1002/jev2.12134
- The paper
- Shi, M., Yang, Q., Monsel, A., Yan, J., Dai, C., Zhao, J., Shi, G., Zhou, M., Zhu, X., Li, S., Li, P., Wang, J., Li, M., Lei, J., Xu, D., Zhu, Y., & Qu, J. (2021). Preclinical efficacy and clinical safety of clinical‐grade nebulized allogenic adipose mesenchymal stromal cells‐derived extracellular vesicles. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.12134
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.